Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the
management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI
will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after
starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI
measurements at 3 months and 1 year as compared to baseline.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborators:
Blue Earth Diagnostics, Inc Dragon Master Foundation